Results 41 to 50 of about 3,144,476 (264)

The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer [PDF]

Frontiers in Molecular Biosciences, 2021
BackgroundColorectal cancer (CRC) is estimated to be one of the most common cancers and the leading cause of cancer-related death worldwide. SOX9 is commonly overexpressed in CRC and participates in drug resistance. In addition, DNA damage repair confers resistance to anticancer drugs.
Yiqiang Liu, Yiqiang Liu, Hong Wu, Tao Luo, Qiyu Luo, Ziyu Meng, Ying Shi, Feifei Li, Feifei Li, Mingxin Liu, Xinhao Peng, Junjie Liu, Chuan Xu, Weizhong Tang   +13 more
openaire   +3 more sources

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma

BMC Cancer, 2020
Background Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses.
Xia Liao, Ge Song, Zihan Xu, Yang Bu, Fan Chang, Fengan Jia, Xuelian Xiao, Xuejiao Ren, Mei Zhang, Qingan Jia   +9 more
doaj   +1 more source

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer

Cancers, 2022
Resistance to treatments is one of the leading causes of cancer therapy failure. Oxaliplatin is a standard chemotherapy used to treat metastatic colorectal cancer. However, its efficacy is greatly reduced by the development of resistances. In a previous study, we deciphered the mechanisms leading to oxaliplatin resistance and highlighted the roles ...
Chocry, Mathieu, Leloup, Ludovic, Parat, Fabrice, Messé, Mélissa, Pagano, Alessandra, Kovacic, Hervé   +5 more
openaire   +2 more sources

MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer

Frontiers in Oncology, 2021
Colorectal cancer is one of the most common malignancies worldwide. Oxaliplatin is the first-line chemotherapeutic agent for the treatment of advanced colorectal cancer. However, acquired resistance to oxaliplatin limits its therapeutic efficacy, and the
Xiao-Lan Qian, Fang Zhou, Song Xu, Jian Jiang, Zhi-Peng Chen, Shao-Kai Wang, Yun Zuo, Chen Ni   +7 more
doaj   +1 more source

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]

, 2006
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
A Ibrahim, A Rennicke, AB Sandler, AP Jekunen, BA Jansen, BA Teicher, Britta K. Stordal, BS Burns, C Kollmannsberger, C Kollmannsberger, CR Culy, D Pectasides, D Pectasides, DC Marks, G Belvedere, G Lenz, G Tisman, GA Hospers, H Kawai, H Kuroda, HD Preisler, HD Preisler, IS Song, J Liu, JM Woynarowski, JM Woynarowski, K Suzukake, K Yamamoto, KV Grech, L Pendyala, L Poulain, M Abal, M Markman, M Mishima, Mary W. Davey, N Jain, N Savaraj, N Thatcher, O Rixe, P Chollet, P Soulie, PJ Kuppen, PR Twentyman, R Sockalingam, RD Christen, Ross A. Davey, S Hector, S Ohta, SG Chaney, SL Lai, SW Johnson, T Fojo, T Moritaka, T Tashiro, V Dieras, VL Locke, WS Hong, Z El Akawi, Z Wang   +58 more
core   +2 more sources

A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling

Frontiers in Oncology, 2021
Numerous colon cancer cases are resistant to chemotherapy based on oxaliplatin and suffer from relapse. A number of survival- and prognosis-related biomarkers have been identified based on database mining for patients who develop drug resistance, but the
Qiu Lin, Li Luo, Hua Wang
doaj   +1 more source

Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]

, 2009
Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
B Stordal, B Stordal, BK Stordal, H Kawai, H Kuroda, M Markman, S Henness, V Dieras   +7 more
core   +2 more sources

Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis

BMC Medicine, 2023
Background Oxaliplatin resistance is a complex process and has been one of the most disadvantageous factors and indeed a confrontation in the procedure of colorectal cancer. Recently, long non-coding RNAs (lncRNAs) have emerged as novel molecules for the
Zhijian Zheng, Ming Wu, Hongyan Li, Wenxia Xu, Mengxiang Yang, Kailing Pan, Yuqi Ni, Ting Jiang, Hongjuan Zheng, Xiayun Jin, Yanfei Zhang, Linchao Ding, Jianfei Fu   +12 more
semanticscholar   +1 more source

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11 [PDF]

Anticancer Research, 2018
Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death. FOLFOX, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, is the first-line chemotherapy for stage III and stage IV CRC. However, patients with
Beibei, Wang, Hisanobu, Ogata, Yuto, Takishima, Shohei, Miyamoto, Hiroyuki, Inoue, Masaki, Kuroda, Kazunari, Yamada, Yasuki, Hijikata, Mutsunori, Murahashi, Hiroyuki, Shimizu, Toshihiko, Okazaki, Yoichi, Nakanishi, Kenzaburo, Tani   +12 more
openaire   +2 more sources

Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K/AKT/mTOR

The FASEB Journal, 2023
Resistance to oxaliplatin (OXA) is a major cause of recurrence in gastric cancer (GC) patients. Autophagy is an important factor ensuring the survival of cancer cells under chemotherapeutic stress. We aimed to investigate the role of OXA‐related genes in
Jun Ren, Zhiqing Hu, G. Niu, Jie Xia, Xing-jie Wang, Runqi Hong, J. Gu, Daorong Wang, Chongwei Ke   +8 more
semanticscholar   +1 more source